{
  "id": "5c910813ecadf2e73f000006",
  "type": "summary",
  "question": "What is opdivo?",
  "ideal_answer": "Opdivo or nivolumab is a treatment for patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28087644"
  ],
  "snippets": [
    {
      "text": "On December 22, 2014, the FDA granted accelerated approval to nivolumab (OPDIVO; Bristol-Myers Squibb) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28087644",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}